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1. Introduction 
Soft tissue sarcoma (STS) represents a heterogeneous group of mesenchymal malignant 
tumors with variable natural history. This term was first introduced to describe a 
circumscribed neoplasm consisting of malignant fat cell occurring principally in the trunk 
(Abernethy, 1817). Nowadays, more than 30 types of STS have been described, and many of 
these present innumerable subtypes. Despite this wide range of entities, they represent less 
than 1% of all types of cancer, but still one of the most therapeutically challenging group of 
tumor (Choong & Rudiger, 2008). Surgery is the keystone of treatment, associated or not to 
adjuvant method, and the two aims are avoid metastatic spread and local relapse. 
Despite advances in local control of the sarcomas, the metastatic disease, which is the 
cause of death for most patients, presents little recent advances. In fact, 10% of patients 
have metastasis at the diagnosis and 25% with localized disease will develop distant 
spread (Delaney et al, 1991). The systemic disease occurs primarily by hematogenic 
spread, and the lungs are the most common distant organs involved by the distant 
metastasis. Some subtypes demonstrated predilection for lymphatic route of 
dissemination such as synovial sarcoma and epithelioid sarcoma while the alveolar 
sarcoma targets the brain involvement. 
In contrast to bone sarcomas, soft tissue malignancies do not respond well to 
chemotherapies schemes. This may be explained by the diversities of subgroups or by 
different factors that affect the prognosis. Therefore, the difficult in treating soft tissue 
sarcomas is determinate which patients will need the adjuvant chemotherapy or radiation 
therapy. The indication of these methods is guided by factors that predict the risk of 
metastatic disease or local recurrence. These factors are called prognostic factors and the 
purpose of this chapter is to define the different prognostic factors of soft tissue sarcoma. 
As a heterogeneous group, the behavior and natural evolution of this tumor are variable, 
but, in general aspects the metastatic spreading is observed in about one third of the 
patients, local relapse is seen in 10% to 30% and the global 5-year survival is 60%. Different 
factors are reported in the literature such as tumor grade, size, location, vascular invasion, 
histological necrosis and presence of cytogenetic markers. However, the importance of each 
factor is unclear. In this chapter we will discuss each prognostic factor including: age, sex, 
location, size, subtype, histological aspects, grade, surgical manipulation, recurrence, 
imunohistochemical pattern, genetic and gene markers.  
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In this chapter the prognostic factors can be separated into three categories: patient factors, 
tumor factors and treatment factors.  
 
 
 
 
 
 
 
 
Fig. 1. Resume of prognostic factor of soft tissue Sarcoma 
2. Prognostic factors 
2.1 Patient factors 
The factors in the literature related to patients are: age, gender and tumor localization. In 
some studies, patients older than 50 years and male are associated with a bad prognostic 
(Gustafson et al. , 1994). Nevertheless, these factors have not been proven of value in 
predicting the risk for local recurrence and metastasis. Although the shorter survival 
observed in the elderly, this seems to be related to tumor size and aggressiveness in this age 
group 35, 36. Even if gender and age had some importance, this seems to be a minor one. 
(Teixeira et al., 2009) 
Localization has also been evaluated as a prognostic factor, according to the segment 
involved, depth or the site related to the anatomical compartments. The depth in relation 
to the muscle fascia is considered a relevant factor for the prognosis, being included in 
some prognostic systems as the AJCC/UICC. However, some studies doubt the validity of 
depth as an isolated factor of worse prognosis, they have found the same survival rate 
when the tumors are adjusted by the histological malignancy and size (Rydholm & 
Gustafson, 2003). 
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The extra compartmental localization also seems to be associated with a bad prognostic. The 
tumors considered extra compartmental usually present more difficult surgical treatment 
and thinner margins, provided that they are in close contact to neurovascular structures. 
Both, the difficult to obtain proper margins and the fact that they are situated in areas with 
rich vascularization and lymphatic drainage help to systemic disseminate and local recur, 
which may explain the results obtained by some studies. (Teixeira et al., 2009) 
More proximal tumors, situated in the scapular or pelvic girdle, in general present delayed 
diagnosis and a bigger size, thus a worse prognosis. On the other side, more distal tumors 
present longer survival rate, but many times they require amputations in order to achieve 
the desired surgical margin. Some studies pointed out a survival rate of 47%, with a local 
recurrence of 35% in tumors of the gluteus area, while tumors in hands and feet present a 
survival rate between 80% and 82% in five years and a local recurrence rate between 17% 
and 21% (Behranwala et al., 2004). Despite the disparity in the survival and local recurrence 
rates, the risk does not seem to be associated with the localization but with the size of the 
tumor in the moment of the diagnostic, as long as distal tumors tend to present earlier and 
smaller. 
2.2 Tumor’s factors 
The factors associated with tumors seem to be the most important ones to determine the 
prognostic of systemic spread. Among them, we call special attention for size, histological 
and genetic aspects and the histological subtypes. 
 
 
 
 
 
 
 
Fig. 2. Large tumors representing an adverse effect in survival 
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The size of the tumor is implicated as an important factor for systemic disease and local 
recurrence. However, there is no consensus determining the cutoff for groups at high risk. 
Some clinical trials use 5cm, 8cm or 10cm as the cutoff. In general, the growth of 5cm in the 
tumor size increases the risk for metastasis 1.5 times (Trovik et al., 1994). Provided that, the 
tumors bigger than 5 cm should been considered as possessing a worse prognostic. 
The histologic grading is a method for stratifying STS into groups of different prognosis 
based on histological aspects such as cellularity, atypia, mitotic index, necrosis, 
pleomorphism and histotype. Most of studies show that high grade of malignancy possess 
a strong influence in developing metastasis and local recurrence, being one of the most 
important independent factors related to the aggressiveness of the STS. However, the lack 
of universal classification, the inaccuracy of each histological component, the examiner 
subjectivity and the different grades of aggressiveness of each histological subtypes 
reduce the reproducibility. The combination of these factors creates several grading 
systems and prognostic models. Some schemes, such as that of the American Joint 
Committee on Cancer (AJCC), have also included nodal involvement. The most widely 
used grading systems include those proposed by the French Federation Nationale des Centres 
de Lutte Contre le Cancer (FNCLCC) and the National Cancer Institute (NCI), the staging 
system established by the AJCC, and a sarcoma-specific mortality nomogram developed 
at the Memorial Sloan-Kettering Cancer Center (MSKCC). Despite of this, the high-grade 
histologic aspect of the tumor must be considered one of most determinant factor in 
overall survival.  
Among the specific histologic aspects, vascular invasion and necrosis seem the most 
important one as an isolated prognostic factor. Vascular invasion represents a well-
established prognostic factor in several tumor types, including malignant melanoma, 
papillary thyroid cancer, endometrial cancer, and testicular cancer. In STS, vascular invasion 
has repeatedly shown prognostic value, but it is generally not applied systematically in 
pathological evaluations. Vascular invasion has been identified with variable prevalence in 
different studies, which may hamper its clinical application. Tumor necrosis has repeatedly 
been established as a negative prognostic factor in STS.23,30-34 It also represents an 
important factor in the FNCLCC and the NCI grading systems, which apply cutoff values of 
15% (microscopic evaluation) and 50% (macroscopic evaluation), respectively. A more 
recent histologic find used in the STS grading is the pattern of growth. Growth pattern was 
classified as pushing or infiltrative, irrespective of the extent of infiltration. Soft tissue 
tumors with microscopically infiltrative pattern of growing have a significantly higher risk 
for local and systemic recurrence compared with a “pushing” growth pattern.  
The histologic subtypes was previously not considered a important factor in the prognosis 
of patients with STS, but the differences in response to adjuvant treatments improve the 
value of the histotypes in predicting metastatic spreading. Some subtypes have a high risk 
to develop distant disease such as synovial sarcoma, epithelioid sarcoma, 
rhabdomyosarcoma and soft tissue Ewing`s sarcoma 
2.2.1 Genetics and molecular aspects 
Prognostication for adults with STS is primarily based on tumor size, histologic grade, 
depth, location, histologic subtype, and the presence or absence of distant metastasis. 
However, recent studies suggest that proliferation markers may improve the prognostic 
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value of standard clinical-pathologic markers. These studies evaluated the DNA activity, 
antigen markers and oncogenes. The first studies have shown that tumor cell proliferative 
activity and/or DNA content are related to the outcome of patients with STS. Several 
methods have been used to assess cell proliferation, including enumeration of mitotic 
figures, thymidine labeling indices, DNA-flow cytometric analysis, and 
immunohistochemical analysis of proteins associated with proliferation. Furthermore, 
multivariate analysis revealed that DNA content was an independent prognostic indicator. 
The widespread availability of DNA analysis by flow cytometry and image analysis, as well 
as the magnitude of the difference in predicting survival, suggest that DNA analysis may be 
useful clinically, for example in selecting candidates for adjuvant systemic therapy. 
However, such statement will require further study (Levine, 1999). .  
The second aspect is histological markers. The most studied is Ki-67, an antigen described in 
1983 as a human nuclear antigen associated with cellular proliferation. Ki-67 expression has 
been found related to other proliferation markers and to p53 mutations. To date, the 
threshold value of immunohistochemical staining for Ki-67 expression that defines a high-
risk lesion for Ki-67 expression is unclear, but is observed in 40% as a “positive” level of 
expression. Although his prognostic significance is unclear, it has been associated with 
prognosis (Ueda et al. 1989). 
The third aspect is the effect of oncogenes. The oncogenes most studied are p53, ras gene 
family, myc, and the RB1.  
The p53 gene, located on human chromosome 17p13, encodes a nuclear phosphoprotein 
involved in transcriptional regulation, translational control, DNA repair, cell cycle 
control, cell differentiation, and apoptosis. The p53 gene is the most commonly mutated 
gene in human solid tumors (Bartek et al., 1991), its mutant expression is observed in 
about 61% of patients with STS (Wadayama et al., 1993) and is associated with poor 
prognosis for distant spread, disease free-survival and drug resistance. Although its 
clinical validity is unclear.  
The ras gene family consists of three genes located on chromosomes 1,11, and 12. Several 
small series of STS have shown low incidence of ras mutations in the range of 3% to 35%. 
Although ras mutations are demonstrable in some types of STS, it is doubtful that this 
represents the original stimulation for malignant transformation or a clinically useful 
prognostic marker.  
The myc oncogene encodes the production of a nuclear phosphoprotein, which binds to 
DNA and can transform cells both in vitro and in vivo [50]. This gene is normally a single 
copy on chromosome 2. Amplification myc has been shown to be a poor prognostic 
indicator for children with neuroblastoma. Several reports have been published of myc 
expression in STS (Dias et al., 1990). In a study of rhabdomyosarcomas, another report 
suggested that myc amplification is limited to the alveolar subtype. A study of 23 STS cases 
found myc amplification in 30% and suggested it was correlated with higher grade and 
poorer survival [54]. Although the data for myc expression/ amplification suggest a 
putative relationship between myc with progression and survival, confirmatory studies are 
needed before validating myc as a prognostic factor in routine clinical practice (Barrios et al., 
1994).  
The c-erbB2 is located on human chromosome17 and encodes a transmembrane protein 
(p185) which has remarkable homology with the epidermal growth factor receptor (EGFR). 
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Few reports have analyzed c-erbB2 amplifications or overexpression in STS. Amplification 
in STS seems to be unusual, occurring in only six of 105 cases in one report (. No studies 
have attached clinical significance to c-erbB2 amplification and/or overexpression. 
Furthermore, the low rates of c-erbB2 alterations do not suggest a role in the initiation or 
progression of STS.  
The human retinoblastoma gene, RB1, located on chromosome 13, is another tumor 
suppressor gene involved in the genesis of STS. Germline’s mutations of RB1 result in the 
hereditary form of retinoblastoma. In addition, somatic mutations of this gene and/or 
absent p110RB protein expression have been observed in various human tumors and tumor 
cell lines. Alterations in RB1 or p110RB protein expression have been observed in up to 70% 
of the STS studied, but do not appear to consistently have clinical prognostic value (Karpeh 
et al.,1995). 
2.3 Treatment factor 
Although STSs do not have a good response as for bone sarcomas, some subtypes can be 
treated with chemotherapy schemes. Systemic chemotherapy is considered the only 
therapeutic option for patients presenting with widely metastatic disease or with locally 
advanced disease not amenable to surgery or radiotherapy. For the majority of these 
patients, cytotoxic chemotherapy should be regarded as palliative, although in a small 
subset of patients long-term survival may be achieved. The standard chemotherapy is 
doxorubicin-based therapy, but others subtypes have a good response to ifosfamide like 
synovial sarcoma. Rhabdomyosarcoma, soft tissue Ewing`s sarcoma and others round cell 
soft tissue tumors have good response to this adjuvant treatment. So the response to the 
treatment can be used as a prognostic factor, but the clinical use is still unclear.  
Other question concerning the influence of the treatment in the prognosis is the previous 
manipulation of the tumor by an unplanned resection. Many times patient and the assistant 
physician came across a diagnosis of an unsuspected sarcoma after a lump resection. This 
manipulation can spread cell tumor. We consider that the clinical problems following an 
unplanned resection of a sarcoma are more dependent of the technical difficulties 
concerning the oncological surgery principles when reoperating the patient than the 
malignance of the tumor itself. If the salvage treatment could be performed appropriately, 
the oncological outcomes may not be influenced. 
Another topic is the effects of a local recurrence in the survival and metastatic disease. There 
is little doubt in the literature that local relapse is associated with a worse prognosis. The 
unsolved issue is whether local relapse is causative. The occurrence of local relapse per se 
might favor the systemic spread of disease and, therefore, directly affect survival, or it might 
simply be a marker of biological tumor aggressiveness. Theoretically, the two mechanisms 
may coexist and possibly interact, with both contributing to the outcome. Some patients had 
a local relapse after surgery performed at nonreferral centers, with unplanned resections 
with marginal or intralesional margins. Others, relapse even with wide margins and 
planned procedure. In the last cases, the recurrence suggests an aggressive sarcoma and 
probably is associated with worse prognosis. If tumor aggressiveness could be objectively 
assessed initially, a different surgical policy might be justified from the very beginning 
(Gronchi et al., 2007). 
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3. Conclusion 
Soft tissue sarcomas have many factors that can influence the overall survival of the 
patients. These factors are related to the patients, tumor and treatment. To achieve the best 
possible result, the physician must take all of them in consideration and try to control the 
factors that have influence in the outcome and are possible to be handled to minimize the 
effects of the others witch he can´t modify. 
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